Health Economics›Clear cell renal cell carcinoma›Metastatic disease second-line

Metastatic disease second-line

Clear cell renal cell carcinoma · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 90 983	28d	9.3 mo	21.4 mo	11	R 1 000 811 PFS proxy	4
Lenvatinib monotherapy Variant #01	—	R 74 494	28d	7.4 mo	—	9	R 670 444 PFS proxy	1
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~8.5 mo	—	~13	~R 744 203 PFS proxy · indirect	1
Everolimus and Lenvatinib Variant #01	—	R 48 788	21d	14.6 mo	—	22	R 1 073 328 PFS proxy	3
Sorafenib monotherapy Variant #04	—	R 37 339	28d	3.9 mo	18.5 mo	5	R 186 694 PFS proxy	5
Sunitinib monotherapy Variant #05	—	R 33 433	28d	~9.1 mo	~34.0 mo	~10	~R 334 331 PFS proxy · indirect	24
Pazopanib monotherapy Variant #01	—	R 22 754	28d	9.2 mo	—	11	R 250 289 PFS proxy	1
Axitinib monotherapy Variant #01	—	R 21 402	28d	8.3 mo	20.1 mo	10	R 214 018 PFS proxy	2
Everolimus monotherapy Variant #01	—	R 18 360	28d	5.5 mo	17.6 mo	6	R 110 158 PFS proxy	10
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	25.0 mo	—	—	1
Placebo Partial	—	—	—	—	15.2 mo	—	—	1
Belzutifan monotherapy Variant #01 Partial	—	—	28d	5.6 mo	21.4 mo	7	—	1

12 of 12 regimens shown